Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 1
1979 1
1981 1
1982 1
1984 1
1986 3
1987 3
1988 2
1990 2
1991 8
1992 2
1993 4
1994 4
1995 6
1996 3
1997 6
1998 3
1999 9
2000 3
2001 3
2002 3
2003 5
2004 2
2005 11
2006 6
2007 6
2008 9
2009 11
2010 11
2011 8
2012 11
2013 11
2014 20
2015 16
2016 16
2017 18
2018 21
2019 16
2020 38
2021 28
2022 37
2023 19
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

356 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis.
Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, Waljee AK, Singal AG. Tzartzeva K, et al. Gastroenterology. 2018 May;154(6):1706-1718.e1. doi: 10.1053/j.gastro.2018.01.064. Epub 2018 Feb 6. Gastroenterology. 2018. PMID: 29425931 Free PMC article.
We compared the performance of surveillance imaging, with or without alpha fetoprotein (AFP), for early detection of HCC in patients with cirrhosis. ...
We compared the performance of surveillance imaging, with or without alpha fetoprotein (AFP), for early detection of HCC in pa …
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators. Zhu AX, et al. Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18. Lancet Oncol. 2019. PMID: 30665869 Clinical Trial.
BACKGROUND: Patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patients with advanced hepatocellular carcinoma and alpha-fetoprotein c …
BACKGROUND: Patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations have poor prognosis …
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators. Bruix J, et al. Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6. Lancet. 2017. PMID: 27932229 Clinical Trial.
Participants were randomly assigned (2:1) by a computer-generated randomisation list and interactive voice response system and stratified by geographical region, Eastern Cooperative Oncology Group performance status, macrovascular invasion, extrahepatic disease, and alpha- …
Participants were randomly assigned (2:1) by a computer-generated randomisation list and interactive voice response system and stratified by …
Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugières L, Perilongo G, Czauderna P, Morland B, Neuwelt EA. Brock PR, et al. N Engl J Med. 2018 Jun 21;378(25):2376-2385. doi: 10.1056/NEJMoa1801109. N Engl J Med. 2018. PMID: 29924955 Free PMC article. Clinical Trial.
METHODS: We randomly assigned children older than 1 month and younger than 18 years of age who had standard-risk hepatoblastoma (3 involved liver sectors, no metastatic disease, and an alpha-fetoprotein level of >100 ng per milliliter) to receive cisplatin alone …
METHODS: We randomly assigned children older than 1 month and younger than 18 years of age who had standard-risk hepatoblastoma (3 involved …
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.
Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, Goff L, Gupta S, Guy J, Harris WP, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Knox JJ, Kortmansky J, Leaf A, Remak WM, Shroff RT, Sohal DPS, Taddei TH, Venepalli NK, Wilson A, Zhu AX, Rose MG. Gordan JD, et al. J Clin Oncol. 2020 Dec 20;38(36):4317-4345. doi: 10.1200/JCO.20.02672. Epub 2020 Nov 16. J Clin Oncol. 2020. PMID: 33197225 Clinical Trial.
Following first-line therapy with sorafenib or lenvatinib, second-line therapy options for appropriate candidates include cabozantinib, regorafenib for patients who previously tolerated sorafenib, or ramucirumab (for patients with alpha-fetoprotein 400 ng/mL), or at …
Following first-line therapy with sorafenib or lenvatinib, second-line therapy options for appropriate candidates include cabozantinib, rego …
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J; ORIENT-32 study group. Ren Z, et al. Lancet Oncol. 2021 Jul;22(7):977-990. doi: 10.1016/S1470-2045(21)00252-7. Epub 2021 Jun 15. Lancet Oncol. 2021. PMID: 34143971 Clinical Trial.
Randomisation was done using permuted block randomisation, with a block size of six, via an interactive web response system, and stratified by macrovascular invasion or extrahepatic metastasis, baseline alpha-fetoprotein, and ECOG performance status. The primary end …
Randomisation was done using permuted block randomisation, with a block size of six, via an interactive web response system, and stratified …
Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.
Shi J, Liu J, Tu X, Li B, Tong Z, Wang T, Zheng Y, Shi H, Zeng X, Chen W, Yin W, Fang W. Shi J, et al. J Immunother Cancer. 2022 Jan;10(1):e003133. doi: 10.1136/jitc-2021-003133. J Immunother Cancer. 2022. PMID: 35101942 Free PMC article. Clinical Trial.
METHODS: We exploited the single-cell approach (cytometry by time of flight (CyTOF)) to analyze peripheral blood mononuclear cells from multicohorts of human samples. Immune signatures for different stages of patients with HCC were systematically profiled and statistically …
METHODS: We exploited the single-cell approach (cytometry by time of flight (CyTOF)) to analyze peripheral blood mononuclear cells from mult …
Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.
Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, Teng M, Syn N, Lim G, Yong JN, Quek J, Xiao J, Dan YY, Siddiqui MS, Sanyal AJ, Muthiah MD, Loomba R, Huang DQ. Tan DJH, et al. Lancet Oncol. 2022 Apr;23(4):521-530. doi: 10.1016/S1470-2045(22)00078-X. Epub 2022 Mar 4. Lancet Oncol. 2022. PMID: 35255263 Free PMC article.
Patients with NAFLD-related hepatocellular carcinoma had larger tumour diameters (p=0.0087), were more likely to have uninodular lesions (p=0.0003), and had similar odds of Barcelona Clinic Liver Cancer stages, TNM stages, alpha fetoprotein concentration, and Easter …
Patients with NAFLD-related hepatocellular carcinoma had larger tumour diameters (p=0.0087), were more likely to have uninodular lesions (p= …
Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis.
Yi X, Yu S, Bao Y. Yi X, et al. Clin Chim Acta. 2013 Oct 21;425:212-20. doi: 10.1016/j.cca.2013.08.005. Epub 2013 Aug 13. Clin Chim Acta. 2013. PMID: 23954771 Review.
BACKGROUND AND OBJECTIVE: Alpha-fetoprotein (AFP) has been widely used as a diagnostic marker. AFP is also increased in patients at high risk for hepatocellular carcinoma (HCC), ie those with chronic hepatitis. The percentage of lens culinaris agglutinin-reactive …
BACKGROUND AND OBJECTIVE: Alpha-fetoprotein (AFP) has been widely used as a diagnostic marker. AFP is also increased in patien …
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
Randomisation was stratified by geographical region, macrovascular portal vein invasion or extrahepatic spread or both, alpha-fetoprotein concentration, and Eastern Cooperative Oncology Group performance status. ...
Randomisation was stratified by geographical region, macrovascular portal vein invasion or extrahepatic spread or both, alpha-feto …
356 results